Meiosis and differentiation of basidium, a defining sexual structure of the phylum Basidiomycota, are genetically integrated by a shared regulatory program to ensure the formation of infectious meiospores in Cryptococcus neoformans.
Nguyen Thi Thuy Ngan, Nhat Thanh Hoang Le ... Jeremy N Day
Despite evidence of significant anti-cryptococcal activity in vitro and animal models, including synergy with other antifungal agents, high-dose tamoxifen has no impact on cerebrospinal fluid sterilization in cryptococcal meningitis.
Andrew Ryan Passer, Shelly Applen Clancey ... Marco A Coelho
A novel form of self-fertility evolved in Cryptococcus depauperatus, a close relative to the human pathogenic Cryptococcus species, in which sexual development is attained by self-signaling of a cognate pheromone and pheromone-receptor pair.
R Blake Billmyre, Shelly Applen Clancey, Joseph Heitman
Eukaryotic pathogens, like Cryptococcus deuterogattii, can use elevated mutation rates to more rapidly adapt to stresses, such as drug challenges, but at the cost of lower fitness in less stressful environments.
Isw1 acts as a master regulator in modulating the expression of drug-resistance genes, and this regulatory mechanism is dependent on the interaction of Isw1 acetylation and ubiquitination.
Centromere deletion in Cryptococcus deuterogattii results in neocentromeres, which span actively expressed genes and at elevated temperatures cen10∆ mutants are unstable leading to chromosome fusion and silencing of the neocentromere.
Benjamin J Chadwick, Tuyetnhu Pham ... Xiaorong Lin
In the fungal pathogen Cryptococcus neoformans, the RAM pathway, potentially through post-transcriptional regulation, plays an essential role in adaptation to host temperature and CO2.
Discovery of a novel mode of sexual reproduction, termed pseudosexual reproduction, in fungi where both parents are required for mating but only one contributes to the meiotic progeny, similar to hybridogenesis in animals.
Morgan A Wambaugh, Steven T Denham ... Jessica CS Brown
Identification and exploitation of interactions between the antifungal drug fluconazole and FDA- approved drugs has the potential to improve treatment for patients with difficult-to-treat systemic fungal infections.